Medtronic credits heart-surgery-device growth as profit tops analyst estimates

Dow Jones
18 Feb

MW Medtronic credits heart-surgery-device growth as profit tops analyst estimates

By Steve Gelsi

Medtronic's adjusted third-quarter profit tops analyst estimates

Medtronic PLC said its revenue grew nearly 3% on strength in its cutting-edge heart-surgery devices as the medical-technology company's adjusted profit topped analyst estimates.

Medtronic $(MDT)$ said its devices for a heart treatment called pulsed-field ablation helped drive growth as it reported adjusted third-quarter earnings of $1.39 a share, ahead of the FactSet consensus estimate of $1.36 a share.

Revenue rose 2.5% to $8.29 billion, slightly below the analyst expectation of $8.33 billion.

The company said its pulsed-field-ablation product revenue increased by more than 20%.

"We are starting to see the results from our long term investments in groundbreaking innovation, such as pulsed field ablation," Chief Executive Geoff Martha said in a prepared statement.

Medtronic still expects to report adjusted earnings of $5.44 a share to $5.50 a share for 2025, compared with the analyst estimate of $5.45 a share.

Medtronic's stock fell 2.4% in premarket trading on Tuesday.

The stock has risen 16.2% so far in 2025, while the S&P 500 SPX has risen 4%.

-Steve Gelsi

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

February 18, 2025 07:19 ET (12:19 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10